Hydroxyurea vs anagrelide

This multicentre, Phase 3b, randomised, open-label, non-inferiority study investigated the cardiac safety, efficacy and tolerability of first-line treatment with anagrelide or hydroxyurea in high-risk ET patients for up to 3 years. This multicentre, Phase 3b, randomised, open-label, non-inferiority study investigated the cardiac safety, efficacy and tolerability of first-line treatment with anagrelide or hydroxyurea in high-risk ET patients for up to 3 years

2024-03-29
    Mesalamine inn
  1. 6%) and 11 patients in the hydroxyurea group (8
  2. Whereas the ANAHYDRET (Anagrelide vs
  3. anagrelide in essential thrombocythemia 35 Australia)
  4. Federal Government
  5. 64-1
  6. Both groups had equivalent long-term control of platelet count
  7. Statistical analysis was performed using fixed effects meta-analysis
  8. Blood 121(23):4778-4781
  9. Serious TEAEs occurred in more patients treated with
  10. anagrelide in essential thrombocythemia 35 Australia)
  11. hydroxyurea vs
  12. Listing a study does not mean it has been evaluated by the U
  13. Hydroxyurea vs
  14. S